• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Johnson & Johnson and U.S. Department of Health & Human Services Expand Agreement to Support Next Phase of COVID-19 Vaccine Candidate Research and Development
NEW BRUNSWICK, N.J., November 14, 2020 – Johnson & Johnson (the Company) announced the expansion to the partnership between its Janssen Pharmaceutical Companies (Janssen) and the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services for the ongoing development of Janssen’s investigational COVID-19 vaccine candidate.Under the amendment, Janssen will commit approximately $604 million and BARDA will commit approximately $454 million to support the ongoing Phase 3 ENS...
Source: Johnson and Johnson - November 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

France limits nicotine sales after coronavirus study  
Stimulant given as ‘likely’ reason for lower infections but authorities stress health risks
Source: FT.com - Drugs and Healthcare - April 24, 2020 Category: Pharmaceuticals Source Type: news

Johnson and Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health and Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson Will Es... Biopharmaceuticals Johnson & Johnson, COVID-19, vaccine
Source: HSMN NewsFeed - March 30, 2020 Category: Pharmaceuticals Source Type: news

Mass. insurers commit to zero-cost coronavirus tests, treatment
Insurance regulators have issued guidance calling for coronavirus tests and treatment be made available to the public at no cost to consumers. Insurers support the mandate, though volatile financials will follow.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 7, 2020 Category: Pharmaceuticals Authors: Jessica Bartlett Source Type: news